Notices. Notice

1,007 words·~5 min read·/register/2000/10/26/00-27453·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4160-01-F DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 00N-1373] Agency Information Collection Activities; Submission for OMB Review; Comment Request; Reporting and Recordkeeping Requirements for Mammography Facilities AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget

(OMB)for review and clearance under the Paperwork Reduction Act of 1995. DATES: Submit written comments on the collection of information by November 27, 2000. ADDRESSES: Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Wendy Taylor, Desk Officer for FDA. FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Reporting and Recordkeeping Requirements for Mammography Facilities—21 CFR Part 900 (OMB Control Number 0910-0309)—Extension Public Law 102-539, the Mammography Quality Standards Act of 1992

(MQSA)(42 U.S.C. 263b) as amended by the Mammography Quality Standards Reauthorization Act (MQSRA) of 1998 (Public Law 105-248) establishes the authority for a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. MQSRA extended the life of the MQSA program for 4 years from its original expiration date of 1998 until 2002, and also modified some of the provisions. The most significant modification from a report and recordkeeping viewpoint under 21 CFR 900.12(c)(2) was that mammography facilities were required to send a lay summary of each examination to the patient. FDA, under this regulation, collects information from accreditation bodies and mammography facilities by requiring each accreditation body to submit an application for approval and to establish a quality assurance program. On the basis of accreditation, facilities are certified by FDA and must prominently display their certificate. FDA uses the information to ensure that private, nonprofit organizations or State agencies meet the standards established by FDA for accreditation bodies to accredit facilities that provide mammography services. Information collected from mammography facilities has also been used to ensure that the personnel, equipment, and quality systems has and continues to meet the regulations under MQSA and will be used by patients to manage their health care properly. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. The most likely respondents to this information collection will be accreditation bodies and mammography facilities seeking certification. In the **Federal Register** of July 17, 2000 (65 FR 44061), the agency requested comments on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: **Table** 1.— **Estimated Annual Reporting Burden** 21 CFR Section No. of Respondents Annual Frequency per Response Total Annual Responses Hours per Response Total Hours Total Capital Costs Total Operating and Maintenance Costs 900.3 6 1 6 60 360 900.3(b)(3) 10 1 10 60 600 $50 900.3(c) 4 0.14 0.56 15 8.4 900.3(e) 1 0.2 0.2 1 0.2 900.3(f)(2) 1 0.2 0.2 1 0.2 900.4(c) 834 1 834 1 834 900.4(e) 10,000 1 10,000 8 80,000 900.4(f) 1,000 1 1,000 14.5 14,500 900.4(h) 6 1 750 6 4,500 900.4(i)(2) 1 1 1 1 1 900.6(c)(1) 1 1 1 1 1 900.11(b)(2) 25 1 25 2 50 900.11(b)(3) 5 1 5 0.5 2.5 900.11(c) 10,000 0.0050 50 20 1,000 $1,000 900.12(c)(2) 9,800 4,080 39,984,000 5 minutes 3,332,000 900.12(j)(1) 10 1 10 1 10 900.15(d)(3)(ii) 10,000 0.0020 20 2 40 $100 900.18(c) 10,000 0.0005 6 2 12 $60 900.18(e) 10 0.1000 1 1 1 $10 Total 3,434,010 $50, $1,170 **Table** 2.— **Estimated Annual Recordkeeping Burden** 1 21 CFR Section No. of Recordkeepers Annual Frequency of Recordkeeping Total Annual Records Hours per Recordkeeper Total Hours Total Operating and Maintenance Costs 900.3(f)(1) 10 130 1,300 200 2,000 900.4(g) 10,000 1 10,000 1 10,000 900.11(b)(1) 1,000 1 1,000 1 1,000 900.12(c)(4) 10,000 1 10,000 1 10,000 900.12(e)(13) 6,000 52 312,000 0.125 39,000 900.12(f) 10,000 1 10,000 1 10,000 900.12(h) 10,000 2 20,000 0.5 10,000 $20,000 Total 82,000 $20,000 1 There are no capital costs associated with this collection of information. All costs of implementing requirements for certification of mammography facilities will be borne by accreditation bodies; the incremental costs that accreditation bodies will face are not expected to be significant. The collection's burden is based upon the estimated number of summaries received by FDA, which in turn is based on the estimated number of examinations expected to be performed in a given year. If mammography examinations increase in number in subsequent years, which is expected for at least the foreseeable future, the annual burden and costs to meet this requirement will increase. Included in the burden estimate is the FDA estimate for mammography lay summaries, which is the practice of notifying the patient in layman's terms of the results of the patient's mammography examination. FDA estimates that there are 9,800 facilities performing mammography in the United States. FDA also estimates that those facilities perform a total of 40 million mammography examinations in a year. In 90 percent of these cases, the notification to the patient can be established by a brief standardized letter to the patient. FDA estimates that preparing and sending this letter will take approximately 5 minutes. In the 10 percent of the cases in which there is a finding of “Suspicious” or “Highly suggestive of malignancy,” the facility is required to make reasonable attempts to ensure that the results are communicated to the patients as soon as possible. FDA believes that this requirement can be met by a 5-minute call from the health professional to the patient. Dated: October 19, 2000. Margaret M. Dotzel, Associate Commissioner for Policy. [FR Doc. 00-27453 Filed 10-25-00; 8:45 am]

Connectionstraces to 3

Traces to 3 documents

U.S. Code

CFR